Chronic Fatigue Syndrome: Finally Treatable? - Retirement Net by Dr. Matthew Edlund, MD, MOH

The Retirement Net Premier retirement living featuring retirement communities and retirement homes in planned active developments. Worldwide resource for active retirement senior communities, rv/resort homes, vacation homes and assisted living facilities. The Retirement Net is the most comprehensive resource of premier retirement communities throughout the world featuring site built homes, manufactured homes, assisted living facilities, planned active retirement communities and various retirement properties worldwide. See also: senior housing, retirement communities, retirement living, elder care network.

Community Search:


Chronic Fatigue Syndrome: Finally Treatable?

Add Article To Favorites   1 Recommendation

A new study offers insight into the nature and treatment of this disease.

Posted November 25, 2011

Chronic fatigue syndrome wrecks people’s lives. It does so physicially, socially, and economically. Looking normal yet not being able to think or work causes enormous hardship compounded by many doctors who think the illness does not really exist—a position health and disability insurance companies are more than happy to endorse. And those who firmly believe it exists are often stumped by how to treat it—beyond stretching, physical activity and psychotherapy.

Now a new study out of Bergen, Norway adds much to the data that chronic fatigue is an autommune disease. If not entirely definitive, it points in the direction that many CFS sufferers and clinicians have argued for decades—that the illness is a disorder of the immune system, is preceded in most cases by some kind of infection, and continues to provoke multiple debilities for a long time.

The Haukelund Study

Many ideas for clinical treatment occur from observing the clinically unexpected. In this case, the Haukelund Hospital researchers were struck by a patient with lymphoma and CFS whose fatigue also improved with treatment. They decided to treat 30 people with CFS, mainly young (average age 37.3 for those treated and 31.5 years for placebo) and female (80%) with rituximab, a potent anti-inflammatory monoclonal antibody that markedly depletes B cells. None of the patients allowed into the study were suffering from endogenous depression, which afflicts a large number of CFS sufferers. None of them showed evidence of the XMRV virus, which previously had been reported as more common in some CFS studies, though critics felt such studies were methodologically flawed.


Some major findings were:

  • About two thirds of the study group saw their fatigue (self-rated) as considerably improved compared to only 13% of the placebo group. Cognitive and other functions also improved, though not necessarily as much.
  • Effects were delayed. Some patients only showed improvement 6-7 months after treatment with the drug.
  • Some people showed marked long term improvement, but only a few (more or less complete in 2/15 on rituximab and 1/15 on placebo at 30-33 months.


  • This is a small study. The number of people treated was not large, the placebo group had the disease longer, and as the authors are very aware, this study needs replication and expansion with ongoing treatment arms.
  • The study group may not be reflective of the majority of CFS patients, many of whom are older, have other intercurrent autoimmune problems (about a fifth of the study group also did) and who often suffer from depression and sleep disorders.
  • Though the authors believe this study shows rituximab is moderating a long term immunological effect through B cells and autoantibodies, nobody has a clear sense of why it works.
  • Rituximab is expensive and has lots of side effects, including infusion reactions, renal failure and possible death.


Despite the problems, there is much cheering in the Bergen study.

First, something works. Most clinical trials of CFS patients, like with acyclovir, show only subsets of patients who experience real improvement.

Second, this study goes a fair way to knocking off the strong belief in the medical community that CFS is “only in people’s heads.” Many with CFS are told that they are depressed—they know that, but also know very well something else is going on that causes that depression.

Third, if something works, further treatment along the lines of oncology/rheumatologic trials may now get funded. Ritixumab and other monoclonal antibodies will be tried, alone or in combination.

The biggest change may occur with public acceptance and awareness. It’s one thing to live with a chronic disease that controls much of your life; it’s another to live with an illness many do not believe exists.

The Bergen study will provoke many more arguments about CFS, particularly what its main manifestations really are and what to do about it. Many sufferers will want immediate treatment with rituximab or other monoclonal antibodies, which may be clinically premature. Immunity is fiendishly complicated, and the effects of monoclonal antibodies on immunity profound.

But the argument that CFS is not related to the immune system may now be less stridently asserted. That would be real progress.

Dr. Matthew Edlund, M.D., M.O.H., is an internationally recognized expert on rest, sleep, and body clocks. His books include The Body Clock Advantage, Designed to Last, and Psychological Time and Mental Illness. His new book, The Power of Rest, shows that rest is a skill that rebuilds, renews, and rewires mind and body, and can increase productivity, health, and pleasure. For more information, visit his website, You can also subscribe to his new Fitcast via the iTunes Store.



Comments (0)

Add A Comment

Want to leave a comment? Sign in.

America's Top 100 Best Master-Planned Communities

My Saved Searches

Sign In or Create your free account to see your saved searches.


Welcome, Guest!   Sign InSign Up